Could a more coordinated EU HTA improve access to new healthcare technologies, favour development of EU-wide evidence development infrastructure and reduce fragmentation? These and other related topics will be discussed on July 9th in Brussels in a meeting organised by the EU Commission and that will involve relevant stakeholders. Here below a link to the meeting webpage:
Today the German G-BA published their decision on added benefit of Tesaro’s orphan drug Zejula (niraparib) for ovarian cancer. The G-BA assigned a ‘non-quantifiable benefit’ to Zejula.
June 1st 2018 – The German G-BA has started the procedure for the benefit assessment of Takeda (Tigenix) Alofisel®️ (darvadstrocel). The publication of the benefit assessment is expected on September 3rd and a final resolution end of November 2018.
link to G-BA webpage
We need to think at new ways to fund general population screening programs
link to article